Knowthestock.com
AXGN - Axogen Inc.

Sell

Weak GrowthEarnings/Profit is Negative
WeakStrong
WeakStrong

40%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 18.81%
Operating Income is Negative but improving
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -3.68%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 4.28
Debt Ratio is 0.46
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.24
Cash Flow is WEAK
Cash from Operations turning Positive
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Axogen Inc. (AXGN) - axogeninc.com
it's time to rethink nerve repair! axogen (nasdaq: axgn) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. people suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. damage may cause loss of function and feeling. axogen is bringing the science of nerve repair to life with its avance® nerve graft which axogen believes is the first and only commercially available allograft for bridging nerve discontinuities, axoguard® nerve connector, a coaptation aid allowing for close approximation of severed nerves, and axoguard® nerve protector that protects nerves during the healing process.
Exchange - NASDAQ
Industry - Surgical and Medical Instrument Manufacturing
Sector - Manufacturing
CEO -
Employees - 418
    Close

    Login/Register

    Home


Cookie Policy
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.